Diabetes UK advice on Avandia
Diabetes UK is recommending that anyone currently taking Avandia (rosiglitazone) should not stop taking the medication without discussing this with their healthcare team first (Diabetes UK)
Licensing drugs for diabetes
Surrogate end points are not enough, robust evidence of benefits and harms is needed (BMJ)
The addition of pioglitazone in type 2 diabetics poorly controlled on insulin therapy: A meta-analysis
Our study implied that in patients with type 2 DM whose control is inadequate on insulin therapy, the additional pioglitazone could significantly improve glucose metabolism and might have a positive effect on important components of the lipid profile, which may have important implications in reducing the risk of cardiovascular disease (European Journal of Internal Medicine)
Ontario economic prosperity threatened by diabetes
Canadian Diabetes Association Releases Ontario Diabetes Report (Canadian Diabetes Association)
Evidence for a Relationship between VEGF and BMI Independent of Insulin Sensitivity by Glucose Clamp Procedure in a Homogenous Group Healthy Young Men
Our data demonstrate a positive correlation between concentrations of circulating VEGF levels and BMI in healthy male subjects under highly controlled conditions. This relationship which is apparently disconnected from insulin sensitivity may be part of some pathogenetic mechanisms underlying obesity and type 2 diabetes (PLoS ONE)
A PPARa Promoter Variant Impairs ERR-Dependent Transactivation and Decreases Mortality after Acute Coronary Ischemia in Patients with Diabetes
The current results define a new genetic disease modifier of outcome after cardiac ischemia that is specific for diabetes (PLoS ONE)
Intracellular molecular effects of insulin resistance in patients with metabolic syndrome
In patients with MetS, we found a reduction of mTOR and other mTOR-related molecules involved in insulin resistance, cell repair, coagulation and vasculogenesis. A reduced expression of mTOR may reflect an increased risk of vascular thrombosis (Cardiovascular Diabetology)
Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol
Endogenous homocysteine exacerbates diabetic cardiomyopathy by attenuating PPAR gamma and inducing E-M uncoupling leading to diastolic dysfunction. PPAR gamma agonist and tempol mitigates oxidative stress and ameliorates diastolic dysfunction in diabetes (Cardiovascular Diabetology)
Glycosmedia Twitter
The Glycosmedia Twitter feed is updated daily and is now available at the bottom of the our home page
Glycosmedia is also available as an App: